科济药业-B(02171.HK):CT1190B获得国家药监局的IND批准用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者

智通财经
Aug 07
【科济药业-B(02171.HK):CT1190B获得国家药监局的IND批准用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者】智通财经APP讯,科济药业-B(02171.HK)发布公告,CT1190B,一种靶向CD19/CD20的通用型 CAR-T细胞产品,已获得国家药监局的IND批准,用于治疗至少二线标准治疗失败的复发/难治性大B细胞淋巴瘤(R/R LBCL)患者。CT1190B的IIT研究结果已在2026年欧洲血液学协会年会上进行壁报展示。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10